Subheading · Chapter 30 · Heading 3002
3002.12: Antisera and other blood fractions
Antisera and blood fractions
3002.12 is the HS subheading for antisera and blood fractions, under heading 3002 in chapter 30.
What you pay
Importing into UK
Rates by national line · UK Global Tariff
UK lines →- 3002 12 00 00 Antisera and other blood fractions Free
Additional duties and import rules
Charges on top of the customs duty, and rules the goods must meet at the border.
Additional duties and charges 1
- Additional dutyAdditional duties 35%
- Applies to goods from
- Belarus, Russia
- Legal act
- 2022 No. 598
- Documents
- 9014
Import requirements 3
- Import controlVeterinary control
- Applies to goods from
- Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antarctica and 232 more
- Legal act
- S.I. 2019/782
- Documents
- C084 Exemption by virtue of Articles 3 and 4 of regulation 2019/2122 (animals intended for scientific purposes, research and diagnostic samples, and samples for product analysis and quality testing).
- N853 Common Health Entry Document for Products (CHED-P) (as set out in Part 2, Section B of Annex II to Commission Implementing Regulation (EU) 2019/1715 (OJ L 261))
- Y058 Exemption by virtue of Article 7 of Commission Delegated Regulation 2019/2122 (Goods which form part of passengers' personal luggage and are intended for personal consumption or use) or Article 10 (small consignments of goods sent to natural persons which are not intended to be placed on the market) of Commission Delegated Regulation 2019/2122
- Y930 The declared goods are not concerned by Commission Implementing Regulation (EU) 2021/632
- Import controlRestriction on entry into free circulation
- Applies to goods from
- Ukraine
- Legal act
- S.I. 2022/395
- Documents
- 9009
- 9010
- 9017
- Import controlImport control - CITES
- Applies to goods from
- all countries
- Legal act
- 2021 No. 54
Preferential rates by country
| Agreement or scheme | Countries | Rate |
|---|---|---|
| standard rate (no agreement) | — | Free |
| DCTS Comprehensive | Afghanistan, Angola, Bangladesh, Benin and 38 moreAfghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Central African Republic, Chad, Comoros, Congo - Kinshasa, Djibouti, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kiribati, Laos, Liberia, Malawi, Mali, Mauritania, Myanmar (Burma), Nepal, Niger, Rwanda, São Tomé & Príncipe, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Timor-Leste, Togo, Tuvalu, Uganda, Yemen, Zambia | Free |
| European Union (including code "EU") | Free | |
| CARIFORUM | Antigua & Barbuda, Bahamas, Barbados, Belize and 10 moreAntigua & Barbuda, Bahamas, Barbados, Belize, Dominica, Dominican Republic, Grenada, Guyana, Jamaica, St Kitts & Nevis, St Lucia, St Vincent & the Grenadines, Suriname, Trinidad & Tobago | Free |
| OCTs (Overseas Countries and Territories) | Anguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands and 7 moreAnguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands, Cayman Islands, Falkland Islands, Montserrat, Pitcairn Islands, South Georgia & South Sandwich Islands, St Helena, Turks & Caicos Islands | Free |
| Central America | Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama | Free |
| SADC EPA | Botswana, Eswatini, Lesotho, Mozambique, Namibia | Free |
| Eastern and Southern Africa States | Madagascar, Mauritius, Seychelles, Zimbabwe | Free |
| CPTPP | Brunei, Malaysia | Free |
| UK–Andorra agreement | Andorra | Free |
| UK–Albania agreement | Albania | Free |
| UK–Australia agreement | Australia | Free |
| UK–Canada agreement | Canada | Free |
| UK–Switzerland agreement | Switzerland | Free |
| UK–Côte d’Ivoire agreement | Côte d’Ivoire | Free |
| UK–Chile agreement | Chile | Free |
| UK–Cameroon agreement | Cameroon | Free |
| UK–Colombia agreement | Colombia | Free |
| UK–Ceuta & Melilla agreement | Ceuta & Melilla | Free |
| UK–Ecuador agreement | Ecuador | Free |
| UK–Egypt agreement | Egypt | Free |
| UK–Fiji agreement | Fiji | Free |
| UK–Faroe Islands agreement | Faroe Islands | Free |
| UK–Georgia agreement | Georgia | Free |
| UK–Ghana agreement | Ghana | Free |
| UK–Israel agreement | Israel | Free |
| UK–India agreement | India | Free |
| UK–Iceland agreement | Iceland | Free |
| UK–Jordan agreement | Jordan | Free |
| UK–Japan agreement | Japan | Free |
| UK–Kenya agreement | Kenya | Free |
| UK–South Korea agreement | South Korea | Free |
| UK–Lebanon agreement | Lebanon | Free |
| UK–Liechtenstein agreement | Liechtenstein | Free |
| UK–Morocco agreement | Morocco | Free |
| UK–Moldova agreement | Moldova | Free |
| UK–North Macedonia agreement | North Macedonia | Free |
| UK–Mexico agreement | Mexico | Free |
| UK–Norway agreement | Norway | Free |
| UK–New Zealand agreement | New Zealand | Free |
| UK–Peru agreement | Peru | Free |
| UK–Papua New Guinea agreement | Papua New Guinea | Free |
| UK–Palestinian Territories agreement | Palestinian Territories | Free |
| UK–Serbia agreement | Serbia | Free |
| UK–Solomon Islands agreement | Solomon Islands | Free |
| UK–Singapore agreement | Singapore | Free |
| UK–San Marino agreement | San Marino | Free |
| UK–Tunisia agreement | Tunisia | Free |
| UK–Türkiye agreement | Türkiye | Free |
| UK–Ukraine agreement | Ukraine | Free |
| UK–Vietnam agreement | Vietnam | Free |
| UK–Samoa agreement | Samoa | Free |
| UK–Kosovo agreement | Kosovo | Free |
| UK–South Africa agreement | South Africa | Free |
UK: imports by month
Main suppliers, last 12 months
| Country | Value | Share | Change |
|---|---|---|---|
| £151.7m | 34% | -9.6% | |
| £107.2m | 24% | -15.2% | |
| £72.9m | 16.3% | -12.2% | |
| £21.2m | 4.7% | -19.6% | |
| £20.6m | 4.6% | -36.9% | |
| £14.9m | 3.3% | +112.8% | |
| £9m | 2% | -93.2% | |
| £9m | 2% | -17% |
Same subheading in other tariffs
World trade in 2024
Trade value (US$) no reported trade < US$508kUS$508k+US$13m+US$396m+> US$2.1bn
Exports: 158
- United States: US$12.4bn
- Germany: US$9.5bn
- Switzerland: US$5.2bn
- Austria: US$4.1bn
- Ireland: US$2.1bn
- Sweden: US$1.9bn
- Spain: US$1.7bn
- Netherlands: US$1.6bn
- Australia: US$1.4bn
- France: US$1.1bn
- Italy: US$915m
- Denmark: US$540m
- Belgium: US$474m
- South Korea: US$422m
- United Kingdom: US$396m
- Poland: US$370m
- Israel: US$226m
- Canada: US$225m
- Czechia: US$185m
- Hungary: US$181m
- New Zealand: US$146m
- India: US$118m
- Japan: US$113m
- Singapore: US$93m
- China: US$81m
- Slovenia: US$71m
- Croatia: US$64m
- Iran: US$53m
- Brazil: US$52m
- Egypt: US$50m
- Lithuania: US$46m
- Mexico: US$29m
- Argentina: US$26m
- Uruguay: US$24m
- Russia: US$18m
- Taiwan: US$18m
- Slovakia: US$14m
- Finland: US$13m
- Latvia: US$11m
- Norway: US$10m
- Hong Kong SAR China: US$9m
- Türkiye: US$9m
- Indonesia: US$9m
- Chile: US$8m
- Paraguay: US$6m
- South Africa: US$4m
- Nicaragua: US$4m
- Costa Rica: US$4m
- Portugal: US$4m
- Thailand: US$4m
- Panama: US$4m
- Vietnam: US$4m
- Ukraine: US$3m
- Sri Lanka: US$3m
- Malaysia: US$3m
- Estonia: US$3m
- Morocco: US$2m
- Cuba: US$2m
- Serbia: US$2m
- Colombia: US$2m
Trade value (US$) no reported trade < US$4mUS$4m+US$42m+US$233m+> US$1.5bn
Imports: 212
- Germany: US$7.9bn
- United States: US$7.9bn
- Switzerland: US$5.4bn
- Austria: US$4bn
- China: US$2.5bn
- Belgium: US$1.8bn
- France: US$1.5bn
- Spain: US$1.5bn
- Italy: US$1.3bn
- Australia: US$1.2bn
- Ireland: US$1.2bn
- Sweden: US$867m
- United Kingdom: US$737m
- Netherlands: US$692m
- Japan: US$574m
- Canada: US$573m
- Türkiye: US$532m
- South Korea: US$504m
- Brazil: US$476m
- Poland: US$426m
- Mexico: US$236m
- Russia: US$233m
- India: US$222m
- Hungary: US$216m
- Saudi Arabia: US$201m
- Iran: US$142m
- Taiwan: US$136m
- Denmark: US$135m
- Czechia: US$131m
- Algeria: US$130m
- Argentina: US$124m
- Greece: US$121m
- Portugal: US$117m
- Iraq: US$109m
- Colombia: US$103m
- Kuwait: US$97m
- Vietnam: US$92m
- Israel: US$92m
- Romania: US$82m
- Indonesia: US$69m
- Thailand: US$68m
- United Arab Emirates: US$65m
- Croatia: US$65m
- Kazakhstan: US$59m
- Slovenia: US$55m
- Hong Kong SAR China: US$55m
- Chile: US$49m
- Guatemala: US$48m
- Jordan: US$46m
- Philippines: US$46m
- Panama: US$44m
- Slovakia: US$43m
- Egypt: US$42m
- Finland: US$42m
- Singapore: US$41m
- Serbia: US$41m
- Tunisia: US$40m
- Malaysia: US$36m
- Peru: US$35m
- Ecuador: US$35m
Top exporters
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$12.4bn | 26.9% | |
| 2 | US$9.5bn | 20.6% | |
| 3 | US$5.2bn | 11.2% | |
| 4 | US$4.1bn | 8.9% | |
| 5 | US$2.1bn | 4.5% | |
| 6 | US$1.9bn | 4.1% | |
| 7 | US$1.7bn | 3.8% | |
| 8 | US$1.6bn | 3.4% | |
| 9 | US$1.4bn | 3.1% | |
| 10 | US$1.1bn | 2.3% |
Top importers
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$7.9bn | 17.2% | |
| 2 | US$7.9bn | 17.1% | |
| 3 | US$5.4bn | 11.7% | |
| 4 | US$4bn | 8.8% | |
| 5 | US$2.5bn | 5.4% | |
| 6 | US$1.8bn | 3.9% | |
| 7 | US$1.5bn | 3.2% | |
| 8 | US$1.5bn | 3.2% | |
| 9 | US$1.3bn | 2.8% | |
| 10 | US$1.2bn | 2.6% |
Import duty on this product around the world 152
The most-favoured-nation (MFN) duty each country applies to goods of this HS subheading: the average over its national tariff lines, with the lowest and highest line where they differ. Goods from countries with a trade agreement often pay less.
- 0%median duty
- 116number of duty-free countries (MFN)
- 15%highest: French Polynesia, Pakistan, India
152
| Importing country | MFN duty | lines from – to | data year |
|---|---|---|---|
| 0% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 3.4% | 0% – 8% | 2023 · HS 2017 | |
| 2.5% | 0% – 3% | 2023 | |
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2022 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2022 · HS 2017 | ||
| 2.5% | 0% – 3% | 2021 · HS 2017 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2022 | ||
| 7% | 5% – 10% | 2023 · HS 2017 | |
| 5% | 2022 | ||
| 0% | 2023 | ||
| 3.4% | 0% – 8% | 2023 · HS 2017 | |
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 5% | 2023 | ||
| 6% | 2023 · HS 2017 | ||
| 3% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0.8% | 0% – 5% | 2023 · HS 2017 | |
| 0% | 2019 · HS 2017 | ||
| 0% | 2022 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 15% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2020 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 10% | 2023 | ||
| 0% | 2023 | ||
| 5% | 2020 · HS 2017 | ||
| 0% | 2022 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 2.5% | 0% – 3% | 2021 · HS 2017 | |
| 5% | 2023 · HS 2017 | ||
| 5% | 2020 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 3.3% | 0% – 15% | 2023 · HS 2017 | |
| 4% | 2021 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 2.5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 11% | 2023 | ||
| 0% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 2.4% | 0% – 8% | 2023 · HS 2017 | |
| 0% | 2023 · HS 2017 | ||
| 2% | 1% – 3% | 2023 | |
| 0% | 2023 | ||
| 2.5% | 0% – 3% | 2021 · HS 2017 | |
| 0% | 2023 | ||
| 0% | 2020 · HS 2017 | ||
| 5% | 2019 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 3% | 0% – 8% | 2023 · HS 2017 | |
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 3.4% | 0% – 8% | 2023 · HS 2017 | |
| 0% | 2023 | ||
| 5% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 |
Tariff data years 2017–2023; rates may have changed since. · UNCTAD TRAINS, accessed via WITS (World Bank)
Classifications and correspondences
Where this HS subheading sits in the United Nations' statistical classifications, and which codes it had in earlier editions of the Harmonized System.
- SITC Rev. 4
- 54163 Antisera & other blood fractions; vaccines
- End use (BEC Rev. 5)
- Intermediate goods · BEC 711220
- CPC 2.1 product
- 35270 Other pharmaceutical products
- ISIC Rev. 4 activity
- 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
Earlier HS editions
| HS | Code | |
|---|---|---|
| 2017 | 3002.12 | unchanged |
| 2012 | 3002.10 | changed |
| 2007 | 2925.29, 2933.29, 2934.99, 2937.90, 3002.10, 3002.20, 3002.90, 3907.20 | changed |
| 2002 | 2925.20, 2933.29, 2934.99, 2937.90, 3002.10, 3002.20, 3002.90, 3907.20 | changed |
| 1996 | 2925.20, 2933.29, 2933.90, 2934.90, 2937.99, 3002.10, 3002.20, 3002.90, 3907.20 | changed |
| 1992 | 2925.20, 2933.29, 2933.59, 2933.90, 2934.90, 2937.99, 3002.10, 3002.20, 3002.90, 3907.20 | changed |
Correspondence tables of the United Nations Statistics Division (UNSD)
Binding rulings for similar goods 7
Decisions of U.S. Customs and Border Protection (CROSS) and HMRC (Advance Tariff Rulings) on goods classified here. A ruling binds only its holder, but shows how the authorities classify similar goods. The descriptions are the authorities’ own, in English.
- N333558 U.S. CBP
The tariff classification of ELOCTATE® [Antihemophilic factor (recombinant), Fc fusion protein] in dosage form, from the United States
- N304133 U.S. CBP
The tariff classification of Andexanet Alfa in bulk form, from Spain
- N294982 U.S. CBP
The tariff classification of IgG Rabbit Gamma Globulin (Millipore Cat #PP63-K). No country of origin was provided.
- H259355 U.S. CBP
Request for a ruling; Classification of reference materials used in VITROS systems
- N283856 U.S. CBP
The tariff classification of Advate®, Obizur® and Vonvendi® imported in dosage form
- 600011309 HMRC
Peripheral Blood Mononuclear Cells or any blood cell with a single nucleus These samples are used for clinical trails, laboratory research and diagnostic testing Packaged using Cell Preparation Tubes or standard sample collection tubes
- 600011305 HMRC
Human blood fractions Samples of plasma and serum Use: clinical trials, laboratory research or diagnostic purposes Packaging: in test tubes or blood collection tubes
Recent rule changes mentioning this code
Acts whose text cites this code or its heading. Check the act itself: a code can be cited for reasons other than a change of its duty.
-
FR Doc. 2026-19498 · 91 FR 60360 · Source: federalregister.gov
-
FR Doc. 2026-14542 · 91 FR 45516 · Source: federalregister.gov
-
FR Doc. 2026-11158 · 91 FR 33854 · Source: federalregister.gov
-
CELEX 32026R0360 · Source: eur-lex.europa.eu
Code history
Since 2017; before, these goods were classified under 3002.10.
The UK Global Tariff has one tariff line for subheading 3002.12; the duty is duty-free.
Subheading 3002.12 is a single line in the EU Combined Nomenclature, where the duty is duty-free.
156 countries pay no duty in the UK thanks to trade agreements and preference schemes such as DCTS Comprehensive and European Union, against a standard rate of Free.
In the UK, additional duty of 35% applies on top of the customs duty to goods from Belarus and Russia.
Imports of antisera and blood fractions into the UK came to £446.4m between September 2025 and August 2026 (down 30% on the year before); Germany supplied 34%, followed by Austria.
In 2024, countries exported antisera and blood fractions worth US$46bn (+8.5% year on year).
The largest exporter was the United States (US$12.4bn), followed by Germany.
Products classified here
Questions and answers
What is the HS code for antisera and other blood fractions?
Antisera and other blood fractions fall under HS subheading 3002.12, part of heading 3002, in section VI of the Harmonized System.
What is the import duty on antisera and other blood fractions in the UK?
Under the UK Global Tariff, imports under 3002.12 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
What is the import duty on antisera and other blood fractions in the EU?
Under the EU Combined Nomenclature, imports under 3002.12 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
Which country exports the most antisera and other blood fractions?
The United States, with US$12.4bn in 2024 (26.9% of world exports).
Which countries can export antisera and blood fractions to the UK duty-free?
156 countries pay no duty under a trade agreement or preference scheme, among them partners under DCTS Comprehensive, European Union, CARIFORUM. The goods must meet the agreement’s rules of origin and the importer needs proof of origin; otherwise the standard rate of Free applies. Pick a country above to see its rate.
Is there anti-dumping duty on antisera and blood fractions?
The UK charges additional duty of 35% on goods from Belarus and Russia. Lower rates apply to the named exporters listed in the measure.
Where does the UK import antisera and blood fractions from?
In the 12 months to August 2026, the largest suppliers were Germany (34%), Austria (24%) and United States (16%), out of total imports of £446.4m.
Typical products
Everyday names, not part of the legal text.